Bruker AXS Appoints Bernard Kolodziej to Vice President of Finance.To download high-resolution, print-ready JPEG JPEG in full Joint Photographic Experts Group Standard computer file format for storing graphic images in a compressed form for general use. JPEG images are compressed using a mathematical algorithm. images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption Business Editors/Health/Medical Writers MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4614012 MADISON, Wis.--(BUSINESS WIRE)--April 13, 2004 Bruker AXS Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces that Bernard Kolodziej has been appointed as its Vice President of Finance. In his new role, Mr. Kolodziej will lead the Bruker AXS global financial function. Mr. Kolodziej joined Bruker AXS in October 1997 and has been CFO See Chief Financial Officer. for the European operations of Bruker AXS since January 1999. Before joining Bruker AXS, from 1995 to 1997, Mr. Kolodziej held several operations and financial positions with the Siemens X-ray business. He has a master's degree in business administration, finance and production engineering from the University of Karlsruhe in Germany. Laura Francis, CFO of Bruker BioSciences Corporation, stated: "We are very pleased to promote Mr. Kolodziej to lead the Bruker AXS financial organization. I have worked with him for a number of years and have been very impressed with his financial and operational abilities. Bernard has been instrumental in our post-merger integration drive and has contributed to our growth over the last few years by establishing additional sales offices around the world." Bernard Kolodziej commented: "I am looking forward to the new challenges of this position, and I will work closely with the Bruker AXS global management team on key issues including sales expansion, margin improvement and certain integration efforts." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4614012 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion